Article

Ocular topical anesthetic drug moves through the pipeline

An ocular topical anesthetic drug (Akten, Akorn Inc.) has received an FDA approvable letter. The letter identified minor CMC deficiencies that must be rectified before approval is granted.

Buffalo Grove, IL-An ocular topical anesthetic drug (Akten, Akorn Inc.) has received an FDA approvable letter. The letter identified several minor CMC deficiencies that must be rectified before final approval is granted, according to the company.

Most of these items have been addressed in the company's previous submissions to the FDA, and the remaining responses will be submitted to the FDA later this month. No additional clinical data are needed, the company added.

Before the approval process is complete, product labeling must be finalized. Proposed labeling has been received by the FDA and final printed labeling will be submitted this month.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
© 2025 MJH Life Sciences

All rights reserved.